Landos Biopharma Inc

Landos Biopharma — Investor Presentation (January 2023)

37 slides from Landos Biopharma's investor presentation, Jan 5, 2023

  1. Slide 1: Corporate Overview January 5, 2023

    Slide 1: Corporate Overview January 5, 2023

    Corporate Overview January 5, 2023

  2. Slide 2: Forward-looking statements

    Slide 2: Forward-looking statements

    This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, prospects, plans and objectives of manage

  3. Slide 3: Landos: The Next Immunology Development Powerhouse

    Slide 3: Landos: The Next Immunology Development Powerhouse

    Landos: The Next Immunology Development Powerhouse 2017: Founding Pioneering Drug Discovery Computational & Immunometabolic Expertise Academic, Entrepreneurial Culture Foundational IP Portfolio 2023: Globally Focused Clinical-Stage BioPharma Innovative Clinical Development Novel Immunology Pipeline

  4. Slide 4: Landos' Novel Immunology Portfolio

    Slide 4: Landos' Novel Immunology Portfolio

    Landos’ Novel Immunology Portfolio 3 14 7 Novel target (NLRX1, LANCL2, PLXDC2) libraries of immunometabolic modulation pathways Potentially first-in-class, once-daily, oral therapeutics upstream of multiple canonical inflammatory/ regulatory pathways Indications in the immunology space targeted by b

  5. Slide 5: Broad Portfolio of Clinical & Pre-clinical Programs

    Slide 5: Broad Portfolio of Clinical & Pre-clinical Programs

    Broad Portfolio of Clinical & Pre-clinical Programs Three Promising Clinical Stage Programs NX-13: A novel, oral, gut-selective NLRX1 agonist in development for the treatment of Ulcerative Colitis and Crohn’s Disease as a once-daily treatment Omilancor: A novel, oral LANCL2 agonist in development fo

  6. Slide 6: Strategic Review: Focused on Most Value-Enhancing Opportunities

    Slide 6: Strategic Review: Focused on Most Value-Enhancing Opportunities

    Strategic Review: Focused on the Most Value-Enhancing Near and Long-Term Opportunities Leverage smart, well-designed clinical trials to advance the strongest programs through clinical development Align our resources with pipeline assets that offer the greatest potential impact and value to sharehold

  7. Slide 7: Landos Strategy: Advancing NX-13 in UC is the Focus

    Slide 7: Landos Strategy: Advancing NX-13 in UC is the Focus

    7 Landos Strategy: Advancing NX-13 in UC is the Focus *NX-13 Phase 1b study was not designed or powered for exploratory clinical endpoints therefore results are hypothesis-generating only Advancing NX-13 is the Top Priority Impressive & Emerging Data Foundation Supports Dual Focus Clear Path Forward

  8. Slide 8: UC is an Attractive & Growing Market Opportunity

    Slide 8: UC is an Attractive & Growing Market Opportunity

    Global Sales ($M): 2020 and 2030 UC is an Attractive & Growing Market Opportunity Source: Clarivate 2020 2030 Global UC Diagnosed Patients: 2020 – 2030 Source: Clarivate Source: 2022 Decision Resource Group (Clarivate) UC Disease Landscape and Forecast including 2030 projected data Global UC Sales (

  9. Slide 9: Clear, Sustainable Entry Point for NX-13

    Slide 9: Clear, Sustainable Entry Point for NX-13

    Aminosalicylates (5-ASA) Mesalamine, Sulfasalazine Immunosuppressants Methotrexate, thiopurines Corticosteroids Budesonide, Prednisone Alpha-4-beta-7 integrin Entyvio TNF-alpha inhibitors Humira, Remicade, Cimzia IL-12/IL-23 Oral Approaches S1P1, JAK, miRNA Pathways MILD MODERATE SEVERE Clear, Susta

  10. Slide 10: Landos' Path Forward

    Slide 10: Landos' Path Forward

    Landos’ Path Forward Strategic focus on NX-13 clinical advancement provides roadmap that aligns with our current resources Phase 2 proof of concept trial for NX-13 on-track to start Q2 2023; top-line data expected in Q4 2024 Broader portfolio with significant optionality for partnerships, developmen

  11. Slide 11: NLRX1 Library

    Slide 11: NLRX1 Library

    NLRX1 Library

  12. Slide 12: NLRX1 Activation Reduces Inflammatory Cytokines, Cells & Signaling Pathways

    Slide 12: NLRX1 Activation Reduces Inflammatory Cytokines, Cells & Signaling Pathways

    NLRX1 Activation Reduces Inflammatory Cytokines, Cells & Signaling Pathways

  13. Slide 13: NLRX1 Library Profile

    Slide 13: NLRX1 Library Profile

    NLRX1 Library Profile Novel NLRX1 Agonist MOA Designed to decrease reactive oxygen species and oxidative stress; decreases pro-inflammatory signals Administration Route Oral, once-daily Pharmacokinetics & Safety in clinical trials to date No on-target toxicities associated with NLRX1 No observed eff

  14. Slide 14: NLRX1 GI Anti-Inflammatory: NX-13 Profile

    Slide 14: NLRX1 GI Anti-Inflammatory: NX-13 Profile

    NLRX1 GI Anti-Inflammatory: NX-13 Profile Mechanism of Action Drug Profile Recent & Upcoming Milestones Targets NLRX1 pathway, a mitochondrial-associated regulatory NOD-like receptor Bimodal MOA aims to decrease reactive oxygen species and oxidative stress, while decreasing pro-inflammatory signals

  15. Slide 15: Phase 1b Study Design of NX-13 in Active UC

    Slide 15: Phase 1b Study Design of NX-13 in Active UC

    Phase 1b Study Design of NX-13 in Active UC IR = Immediate Release; MR = Modified Release Note: Study was not designed or powered for exploratory clinical endpoints therefore results are hypothesis-generating only Group 1: NX-13 250mg IR n=12 Group 4: Placebo n = 4 Week 2 Week 4 EOT Group 3: NX-13 5

  16. Slide 16: NX-13 Treated Patients Experienced Reductions in Multiple Clinical Measures

    Slide 16: NX-13 Treated Patients Experienced Reductions in Multiple Clinical Measures

    Clinical Response Defined as CFB of at least -3, or -30% in Mayo Score Histologic Remission Geboes <3.1, no increased neutrophils in the LP Endoscopic Response MES CFB of at least -1 NX-13 Treated Patients Experienced Reductions in Multiple Clinical Measures after 4 weeks IR= Immediate Release; MR=

  17. Slide 17: NX-13 Supported Symptomatic Remission in Rectal Bleeding & Stool Frequency

    Slide 17: NX-13 Supported Symptomatic Remission in Rectal Bleeding & Stool Frequency

    Patients in the 250mg group had the greatest reduction of Rectal Bleeding and Stool Frequency at 2 weeks, with further reduction at 4 weeks Majority of patients saw complete resolution of BOTH rectal bleeding and stool frequency after 4 weeks of treatment with NX-13 250mg, once daily NX-13 Supported

  18. Slide 18: NX-13 was Well-Tolerated & Shows Promising Signs of Clinical Improvement

    Slide 18: NX-13 was Well-Tolerated & Shows Promising Signs of Clinical Improvement

    Generally well tolerated, consistent with non-clinical, Phase 1a data No Serious Adverse Events 3 unrelated Adverse Events (AEs) of note 4 weeks of low dose, immediate release, once daily treatment induced: Clinical response in 8/11 patients Clinical remission in 3/11 patients Endoscopic and Histolo

  19. Slide 19: What's Next: Study Design for NX-13 Phase 2 Proof of Concept Trial

    Slide 19: What's Next: Study Design for NX-13 Phase 2 Proof of Concept Trial

    What’s Next: Study Design for NX-13 Phase 2 Proof of Concept Trial OUR GOAL | Generate as much meaningful data as possible — as quickly as possible — to build on our already impressive data foundation. TIMING | On-track to initiate Phase 2 trial in Q2 2023; Expecting to report topline data by Q4 202

  20. Slide 20: Preclinical Programs in the NLRX1 Agonist Library

    Slide 20: Preclinical Programs in the NLRX1 Agonist Library

    Preclinical Programs in the NLRX1 Agonist Library 20 LABP-73 for Respiratory Inflammation LABP-66 for CNS Inflammation Key Indications Asthma, COPD MS, AlzD Administration Oral, once-daily Oral, once-daily Development Stage Preclinical Development Preclinical Development Additional Information MOA s

  21. Slide 21: LANCL2 Library

    Slide 21: LANCL2 Library

    LANCL2 Library B1OPHARMA

  22. Slide 22: LANCL2 Activity Exerts Anti-Inflammatory Effects within GI Tract

    Slide 22: LANCL2 Activity Exerts Anti-Inflammatory Effects within GI Tract

    LANCL2 Activity Exerts Anti-Inflammatory Effects within GI Tract

  23. Slide 23: LANCL2 Library Profile

    Slide 23: LANCL2 Library Profile

    LANCL2 Library Profile Novel LANCL2 Agonist MOA Downregulation of pro-inflammatory signals Increase in T regs and anti-inflammatory signals Administration Route Oral, once-daily Pharmacokinetics & Safety in clinical trials to date No on-target toxicities associated with LANCL2 No observed effects of

  24. Slide 24: LANCL2 Oral GI Anti-Inflammatory: Omilancor Profile

    Slide 24: LANCL2 Oral GI Anti-Inflammatory: Omilancor Profile

    LANCL2 Oral GI Anti-Inflammatory: Omilancor Profile Mechanism of Action Drug Profile Recent Milestones Targets LANCL2 pathway, a G-coupled protein receptor on the cell surface Bimodal MOA aims to stabilize regulatory T cell activity while down-regulating proinflammatory cytokine expression Orally ac

  25. Slide 25: Phase 2 Study of Omilancor in Active UC (BT-11-201)

    Slide 25: Phase 2 Study of Omilancor in Active UC (BT-11-201)

    Phase 2 Study of Omilancor in Active UC (BT-11-201) Primary Objective The primary objective of this proof-of-concept study was to establish the efficacy of oral BT-11 in inducing clinical remission at Week 12 in subjects with mild-to-moderate UC Key Inclusion Criteria Male and female subjects with m

  26. Slide 26: Omilancor Induced Remission in Active UC

    Slide 26: Omilancor Induced Remission in Active UC

    Total Population Clinical Remission Omilancor Induced Remission in Active UC *Clinical Remission defines as Mayo Score less than or equal to 2, with no subscore above 1 Total Population (baseline Total Mayo 4-10) Severity Analysis (baseline Total Mayo≥8) Average: Placebo (n = 66) Omilancor 440 mg (n

  27. Slide 27: Omilancor was Active in a More Severe UC Population

    Slide 27: Omilancor was Active in a More Severe UC Population

    Omilancor was Active in a More Severe UC population (Total Mayo ≥8) *Clinical Remission defines as Mayo Score less than or equal to 2, with no subscore above 1; endoscopic remission MES≤1; Mucosal healing MES≤1, Geboes<3.1 Clinical remission* (Delta 14 versus placebo) Endoscopic remission* (Delta 16

  28. Slide 28: Omilancor GI Summary & Next Steps

    Slide 28: Omilancor GI Summary & Next Steps

    Omilancor GI Summary & Next Steps WHAT’S NEXT Continue to Assess Reformulation to Improve Efficacy & Replicability of Response What we learned in the phase 2 trial: What we still need to determine: Omilancor was highly active and induced high levels (>20%) of both clinical and endoscopic remission,

  29. Slide 29: Systemic LANCL2 Activation Aims to Enhance Tolerability & Restore Homeostasis

    Slide 29: Systemic LANCL2 Activation Aims to Enhance Tolerability & Restore Homeostasis

    Systemic LANCL2 Activation Aims to Enhance Tolerability & Restore Homeostasis in Immune Cells

  30. Slide 30: LANCL2 Oral Systemic Anti-Inflammatory: LABP-104 Profile

    Slide 30: LANCL2 Oral Systemic Anti-Inflammatory: LABP-104 Profile

    LANCL2 Oral Systemic Anti-Inflammatory: LABP-104 Profile Mechanism of Action Drug Profile Recent & Upcoming Milestones Targets LANCL2 pathway, a G-coupled protein receptor on the cell surface Orally active with systemic distribution, allowing broad target engagement In development for Systemic Lupus

  31. Slide 31: Preclinical Programs in the LANCL2 Agonist Library

    Slide 31: Preclinical Programs in the LANCL2 Agonist Library

    Preclinical Programs in the LANCL2 Agonist Library 31 Note: Advancing NX-13 in UC is the Company’s current focus and top priority PsO: Psoriasis; A.Derm: Atopic Dermatitis; NASH: Non-Alcoholic Steatohepatitis; T1D: Type 1 Diabetes TOPICAL OMILANCOR for Dermatological Inflammation LABP-111 for Metabo

  32. Slide 32: PLXDC2 Family

    Slide 32: PLXDC2 Family

    PLXDC2 Family B1OPHARMA

  33. Slide 33: Activation of PLXDC2 Suppresses Inflammation & Angiogenesis

    Slide 33: Activation of PLXDC2 Suppresses Inflammation & Angiogenesis

    Activation of PLXDC2 in Immune & Non-Immune Cells Suppresses Inflammation & Angiogenesis

  34. Slide 34: PLXDC2 Anti-Inflammatory: LABP-69 Profile

    Slide 34: PLXDC2 Anti-Inflammatory: LABP-69 Profile

    Designed to decrease reactive oxygen species, oxidative stress, pro-inflammatory signals & angiogenesis Novel PLXDC2 Agonist MOA MOA: Evidence in 2 RA rodent models Next Step: IND-enabling toxicology Ongoing Preclinical Development Rheumatoid Arthritis Diabetic Nephropathy Key Indications PLXDC2 Ant

  35. Slide 35: LABP-69 Reduced Disease Severity In Rat Model Of Rheumatoid Arthritis

    Slide 35: LABP-69 Reduced Disease Severity In Rat Model Of Rheumatoid Arthritis

    Hind Paw Size Histologic Disease Severity LABP-69 Reduced Disease Severity In Rat Model Of Rheumatoid Arthritis 1/4 Oral LABP-69 treatment resulted in: Decreased paw swelling as an indication of inflammation within the joint Reduced histologic cartilage damage, disorganization, and pannus formation

  36. Slide 36: Landos' Path Forward

    Slide 36: Landos' Path Forward

    Landos’ Path Forward Strategic focus on NX-13 clinical advancement provides roadmap that aligns with our current resources Phase 2 proof of concept trial for NX-13 on-track to start Q2 2023; top-line data expected in Q4 2024 Broader portfolio with significant optionality for partnerships, developmen

  37. Slide 37: Landos Biopharma

    Slide 37: Landos Biopharma

    LANDOS BIlOPHARMA

Source: SEC EDGAR · 8-K filed Jan 5, 2023

More decks from Landos Biopharma Inc